The Scottish Dental Clinical Effectiveness Programme (SDCEP) is an initiative of the National Dental Advisory Committee (NDAC) and part of NHS Education for Scotland (NES). SDCEP provides user-friendly, evidence-based guidance to support dental teams to provide high quality healthcare that is safe, effective and person centred.
Here a a collection of the most relevant documents for those undertaking referrals.
- Anticoagulants or Antiplatelet
- Drug Prescribing
The provision of adequate anxiety control is an integral part of the practice of dentistry. The aim of the guidance is to promote good clinical practice through recommendations for the provision of conscious sedation for dental care that is both safe and effective.
Conscious Sedation in Dentistry was developed by a group of professionals with a particular interest and experience in dental sedation and was first published in 2006. The Guidance Development Group reconvened to review the guidance in 2011 and agreed that, at that stage, fully updating the guidance was not necessary. Instead, a second edition comprising a partial update was considered to be sufficient to incorporate certain developments that had occurred since the guidance was first published. As the guidance was only undergoing a partial update, a second consultation was not carried out. However, like the first edition, the updated guidance was subject to peer review prior to finalising for publication.
There is an increased risk of oral health complications for patients prescribed bisphosphonate drugs (Bisphosphonate-related Osteonecrosis of the Jaw). This guidance provides clear and practical advice for dentists in primary care on how to provide care for patients prescribed these drugs. The guidance is also of relevance to prescribers and dispensers of bisphosphonates and to patients.
The guidance has been developed by a Guidance Development Group comprising professionals from a range of relevant healthcare disciplines and a patient representative, assisted by our Programme Development Team. A rapid process was adopted to develop this guidance. A draft was made available for consultation for a four week period in October 2010. All responses received were considered by the Guidance Development Group and the guidance was revised accordingly before finalising for publication
Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs provides recommendations and practical advice to inform bleeding risk assessment and decision making for the treatment of this patient group. Information about the newer generation anticoagulants and antiplatelet drugs as well as the more established medications is included.
The guidance is aimed primarily at dentists, hygienists and therapists in primary care dental practice and will also be of relevance to the secondary care dental service, those involved in dental education and undergraduate trainees.
The guidance is based on a review of available evidence and the opinion of dental and medical experts and experienced practitioners and has been subject to open consultation prior to finalising for publication.
Dental prescribing within the NHS is restricted to drugs included in the Dental Practitioner’s Formulary, which is incorporated within the British National Formulary (BNF) and BNF for Children (BNFC). To facilitate easy access to information that is most relevant to primary care dental practice, Drug Prescribing For Dentistry brings together advice on dental prescribing from the BNF and BNFC and presents it in a problem-orientated style. The information on drug prescribing in this second edition of the guidance is based on BNF 61 and BNFC 2011. Advice on drugs used to manage medical emergencies is also provided, based on information provided in BNF 61 and BNFC 2011, and guidance published by the Resuscitation Council (UK).
The guidance is suitable for informing dental practitioners in the primary care sector, and applies to all patients, including adults, children and those with special needs, who would normally be treated in this sector. The guidance does not include advice on prescribing for those in a secondary care environment or for practitioners with special expertise who may prescribe a wider range of drugs. The intention is for the guidance to be used in conjunction with the BNF and BNFC.